Methotrexate topical - NanoCyteAlternative Names: IR methotrexate - NanoCyte
Latest Information Update: 31 Mar 2011
At a glance
- Originator NanoCyte
- Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 31 Mar 2011 Preclinical development is ongoing in Israel
- 23 Aug 2004 Preclinical trials in Psoriasis in Israel (Topical)